Researchers identify ’born to be bad’ colorectal cancer tumours

An international research team has identified ’born to be bad’ colorectal tumours in people with early stage cancer, which could help medical experts pinpoint and better treat aggressive tumours.

The team from Monash University , CRUK Beatson Institute in Glasgow and Queens University in Belfast found a feature of early-stage colorectal tumours in mice and humans, known as TGF? signalling, that is active in tumour cells and is profoundly tumour-promoting.

In this group of patients, epithelial TGF? signalling predicted how aggressive, treatment-resistant and lethal the cancer was/is.

Until now, such signalling pathways that identify the ’bad’ tumours had only been found in late stage cancers. It is believed to be the first time they have been identified in early stage colorectal cancer.

Globally, 1.9 million colorectal cases were diagnosed in 2020, which is projected to grow to 2.2 million by 2030.

Published in Nature Communications , the study used molecular profiling to identify ’born to be bad’ colorectal tumours that were likely to progress quickly due to the activation of TGF? signalling in the tumour epithelium.

Joint first author Dr Dustin Flanagan , of the Monash Biomedicine Discovery Institute , said the findings could lead to improved and more personalised treatments for colorectal cancer patients who were likely to experience a relapse.

He said the TGF? signalling effectively gave ’born to be bad’ tumours the help they needed to become really nasty. Identifying this unique feature early could strongly predict whether they would become aggressive.

"This suggests tumour cells with ’aggressive potential’ are pre-programmed from an early stage or ’born to be bad’, rather than acquire these qualities over time," Dr Flanagan said. "This challenges how we typically think about cancer progression, but also how and when to treat patients.

"We looked at patients diagnosed with early-stage (Stage I) colon cancer and noticed those who would go on to relapse had high levels of TGF? signalling in the tumour epithelium.

"TGF? is a cytokine that normally prevents cells from growing out of control. In other words, it’s a tumour suppressor, especially in early stages of the disease. But if the cancer mutates to become insensitive to TGF’, then TGF? ends up behaving as a tumour promoter.

"We showed that tumour cells with active TGF? signalling stimulate additional growth-promoting pathways, exposing an Achilles heel which we can exploit with targeted therapies.

"Collectively, our findings have major implications for the prognosis and therapeutic management of colorectal cancer."

Dr Flanagan said he and his colleagues were now collaborating with researchers in Italy and the UK to translate the findings using patient-derived organoid and xenograft (transplant) models.

"We are keen to test whether the same disease mechanisms (i.e. TGF? signalling) used by primary colon tumours cells are also adopted by tumour cells that migrate to other sites in the body to establish metastatic disease," he said.

"We will explore and identify other potential indicators of ’born to be bad’ colorectal cancer that can be harnessed in a similar way to active TGF? signalling."

Read the full paper published in Nature Communications, titled Epithelial TGF? engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features

Registered higher education provider

ABN 12 377 614 012

CRICOS Provider Number

Monash University: 00008C
Monash College: 01857J